Metastatic Cancer - Pipeline Review H2 2013:New Industry Analysis Report

250 views
192 views

Published on

Metastatic Cancer - Pipeline Review H2 2013:New Industry Analysis Report @ http://www.researchmoz.us/metastatic-cancer-pipeline-review-h2-2013-report.html

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
250
On SlideShare
0
From Embeds
0
Number of Embeds
5
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Metastatic Cancer - Pipeline Review H2 2013:New Industry Analysis Report

  1. 1. Metastatic Cancer - Pipeline Review, H2 2013 Metastatic Cancer - Pipeline Review, H2 2013 Summary Global Markets Directs, 'Metastatic Cancer - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Cancer. Metastatic Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Metastatic Cancer. - A review of the Metastatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Metastatic Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Metastatic Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Metastatic Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that Metastatic Cancer - Pipeline Review, H2 2013
  2. 2. drove them from pipeline. Table Of Contents table Of Contents 2 list Of Tables 5 list Of Figures 6 introduction 8 global Markets Direct Report Coverage 8 metastatic Cancer Overview 9 therapeutics Development 10 an Overview Of Pipeline Products For Metastatic Cancer 10 metastatic Cancer Therapeutics Under Development By Companies 12 metastatic Cancer Therapeutics Under Investigation By Universities/institutes 16 late Stage Products 17 comparative Analysis 17 mid Clinical Stage Products 18 comparative Analysis 18 early Clinical Stage Products 19 comparative Analysis 19 discovery And Pre-clinical Stage Products 20 comparative Analysis 20 metastatic Cancer Therapeutics - Products Under Development By Companies 21 metastatic Cancer Therapeutics - Products Under Investigation By Universities/institutes 25 companies Involved In Metastatic Cancer Therapeutics Development 26 bristol-myers Squibb Company 26 boehringer Ingelheim Gmbh 27 f. Hoffmann-la Roche Ltd. 28 amgen Inc. 29 eli Lilly And Company 30 merck & Co., Inc. 31 ziopharm Oncology, Inc. 32 aphios Corporation 33 supergen, Inc. 34 celgene Corporation 35 anticancer, Inc. 36 merck Kgaa 37 entremed, Inc. 38 circadian Technologies Limited 39 tapimmune Inc. 40 hanall Pharmaceutical Co., Ltd. 41 galapagos Nv 42 cancer Research Technology Limited 43 glycotope Gmbh 44 Metastatic Cancer - Pipeline Review, H2 2013
  3. 3. altor Bioscience Corporation 45 provecs Medical Gmbh 46 alethia Biotherapeutics Inc. 47 five Prime Therapeutics, Inc. 48 merrimack Pharmaceuticals, Inc. 49 deciphera Pharmaceuticals, Llc 50 msm Protein Technologies, Inc. 51 vascular Biogenics Ltd. 52 advenchen Laboratories, Llc 53 globeimmune, Inc. 54 bind Biosciences, Inc. 55 tracon Pharmaceuticals, Inc. 56 medestea Research & Production S.p.a. 57 pharmabcine, Inc. 58 eci, Inc. 59 faron Pharmaceuticals, Ltd. 60 incuron 61 angiolab, Inc. 62 gradalis Inc. 63 immunovative Therapies, Ltd. 64 metastatic Cancer - Therapeutics Assessment 65 assessment By Monotherapy Products 65 assessment By Route Of Administration 66 assessment By Molecule Type 68 drug Profiles 70 di-17-e-6 - Drug Profile 70 ridaforolimus - Drug Profile 72 solitomab - Drug Profile 76 enmd-2076 - Drug Profile 78 bms-833923 - Drug Profile 80 im-01 - Drug Profile 82 at-9283 - Drug Profile 83 at-7519 - Drug Profile 85 at-13387 - Drug Profile 88 cetuximab Biobetter - Drug Profile 91 aph-0912 - Drug Profile 92 fp-1039 - Drug Profile 93 cbl-0137 - Drug Profile 95 irinotecan Sucrosofate - Drug Profile 96 palifosfamide Tromethamine - Drug Profile 98 ab-16b5 - Drug Profile 100 adhtap - Drug Profile 101 yn-968d1 - Drug Profile 103 Metastatic Cancer - Pipeline Review, H2 2013
  4. 4. vb-111 - Drug Profile 106 panitumumab - Drug Profile 107 alt-801 - Drug Profile 110 glpg-0187 - Drug Profile 112 gi-6207 - Drug Profile 113 vgx-100 - Drug Profile 114 docetaxel Targeted Nanoparticles - Drug Profile 116 aptamer-targeted Sirna - Drug Profile 118 afatinib - Drug Profile 119 hl-156can - Drug Profile 121 ly-2334737 - Drug Profile 122 ly-2780301 - Drug Profile 123 arry-382 - Drug Profile 124 mtlh-003 - Drug Profile 125 mtlh-004 - Drug Profile 126 emd-521873 - Drug Profile 127 it-235 - Drug Profile 128 oncase-peg - Drug Profile 129 trc-102 - Drug Profile 130 msb-0010360 - Drug Profile 132 trastuzumab Biobetter - Drug Profile 133 gi-6301 - Drug Profile 135 pbi-shrna Stmn1 Lp - Drug Profile 136 msm-057 - Drug Profile 137 msm-165 - Drug Profile 138 msm-112 - Drug Profile 139 dcc-2909 - Drug Profile 140 metvac Vaccine - Drug Profile 141 ttac-0001 - Drug Profile 142 ly-3039478 - Drug Profile 143 cytopep - Drug Profile 144 short Peptide Inhibitors Of Mt1 Mmp - Drug Profile 145 prx-003 - Drug Profile 146 msb-0010718c - Drug Profile 147 phospholipase D Inhibitors - Drug Profile 148 monoclonal Antibody Targeting Tyrosine Phosphatase Dep-1 - Drug Profile 149 abc Transporter Inhibitors - Drug Profile 150 anti-s100a4 Monoclonal Antibody - Drug Profile 151 kn-014 - Drug Profile 152 u-94 - Drug Profile 153 integrin Alpha5beta1 Inhibitor - Drug Profile 154 q-4 - Drug Profile 155 tumour Anti Invasive Compounds - Drug Profile 156 Metastatic Cancer - Pipeline Review, H2 2013
  5. 5. hsa-timp-2 - Drug Profile 157 amx-3002 - Drug Profile 158 dp-6865 - Drug Profile 159 laulimalide Derivatives - Drug Profile 160 pegylated Il-10 - Drug Profile 161 metastatic Cancer Therapeutics - Drug Profile Updates 162 metastatic Cancer Therapeutics - Discontinued Products 206 metastatic Cancer Therapeutics - Dormant Products 207 metastatic Cancer - Product Development Milestones 209 featured News & Press Releases 209 appendix 214 methodology 214 coverage 214 secondary Research 214 primary Research 214 expert Panel Validation 214 contact Us 215 disclaimer 215 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Metastatic Cancer - Pipeline Review, H2 2013

×